Biotest Aktiengesellschaft (BIO3) - Cash Flow Conversion Efficiency

Latest as of March 2025: -0.114x

Based on the latest financial reports, Biotest Aktiengesellschaft (BIO3) has a cash flow conversion efficiency ratio of -0.114x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-58.10 Million ≈ $-67.93 Million USD) by net assets (€509.60 Million ≈ $595.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Biotest Aktiengesellschaft (BIO3) total market value for the company's overall valuation and market capitalisation.

Biotest Aktiengesellschaft - Cash Flow Conversion Efficiency Trend (2002–2024)

This chart illustrates how Biotest Aktiengesellschaft's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Biotest Aktiengesellschaft Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Biotest Aktiengesellschaft ranked by their cash flow conversion efficiency. Explore Biotest Aktiengesellschaft (BIO3) cash flow quality to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Liberty Broadband Srs A
NASDAQ:LBRDA
-0.012x
Ballard Power Systems Inc
TO:BLDP
-0.038x
Hunan Airbluer Environmental Protection Technology Co. Ltd.
SHE:301259
N/A
King-Strong New Material Technology Co Ltd
SHE:300629
-0.006x
Shanghai Kelai Mechatronics
SHG:603960
0.027x
Chapters Group AG
XETRA:CHG
0.040x
ACNB Corporation
NASDAQ:ACNB
-0.008x
Mengtian Home Group Inc.
SHG:603216
N/A

Annual Cash Flow Conversion Efficiency for Biotest Aktiengesellschaft (2002–2024)

The table below shows the annual cash flow conversion efficiency of Biotest Aktiengesellschaft from 2002 to 2024. View Biotest Aktiengesellschaft share price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 €530.70 Million
≈ $620.44 Million
€60.90 Million
≈ $71.20 Million
0.115x +2220.40%
2023-12-31 €498.90 Million
≈ $583.27 Million
€-2.70 Million
≈ $-3.16 Million
-0.005x +95.04%
2022-12-31 €371.10 Million
≈ $433.85 Million
€-40.50 Million
≈ $-47.35 Million
-0.109x -222.46%
2021-12-31 €380.40 Million
≈ $444.73 Million
€33.90 Million
≈ $39.63 Million
0.089x +335.65%
2020-12-31 €441.60 Million
≈ $516.28 Million
€-16.70 Million
≈ $-19.52 Million
-0.038x +46.32%
2019-12-31 €476.90 Million
≈ $557.55 Million
€-33.60 Million
≈ $-39.28 Million
-0.070x +30.22%
2018-12-31 €495.20 Million
≈ $578.94 Million
€-50.00 Million
≈ $-58.46 Million
-0.101x -202.38%
2017-12-31 €347.80 Million
≈ $406.61 Million
€34.30 Million
≈ $40.10 Million
0.099x -46.02%
2016-12-31 €360.70 Million
≈ $421.70 Million
€65.90 Million
≈ $77.04 Million
0.183x +97.71%
2015-12-31 €412.30 Million
≈ $482.02 Million
€38.10 Million
≈ $44.54 Million
0.092x +489.25%
2014-12-31 €480.20 Million
≈ $561.40 Million
€-11.40 Million
≈ $-13.33 Million
-0.024x -51.90%
2013-12-31 €460.70 Million
≈ $538.61 Million
€-7.20 Million
≈ $-8.42 Million
-0.016x -116.63%
2012-12-31 €369.43 Million
≈ $431.91 Million
€34.73 Million
≈ $40.60 Million
0.094x -54.92%
2011-12-31 €346.67 Million
≈ $405.29 Million
€72.28 Million
≈ $84.50 Million
0.208x -17.59%
2010-12-31 €307.61 Million
≈ $359.63 Million
€77.83 Million
≈ $90.99 Million
0.253x +115.51%
2009-12-31 €269.86 Million
≈ $315.50 Million
€31.68 Million
≈ $37.04 Million
0.117x -13.75%
2008-12-31 €253.37 Million
≈ $296.22 Million
€34.49 Million
≈ $40.32 Million
0.136x -5.47%
2007-12-31 €225.76 Million
≈ $263.94 Million
€32.51 Million
≈ $38.01 Million
0.144x -1.85%
2006-12-31 €179.31 Million
≈ $209.64 Million
€26.31 Million
≈ $30.76 Million
0.147x -12.46%
2005-12-31 €168.97 Million
≈ $197.55 Million
€28.32 Million
≈ $33.11 Million
0.168x -28.46%
2004-12-31 €107.97 Million
≈ $126.22 Million
€25.29 Million
≈ $29.57 Million
0.234x +46.49%
2003-12-31 €103.29 Million
≈ $120.75 Million
€16.52 Million
≈ $19.31 Million
0.160x +619.93%
2002-12-31 €110.79 Million
≈ $129.53 Million
€2.46 Million
≈ $2.88 Million
0.022x --

About Biotest Aktiengesellschaft

XETRA:BIO3 Germany
Market Cap
$656.94 Million
€561.91 Million EUR
Market Cap Rank
#10969 Global
#1260 in Germany
Share Price
€28.40
Change (1 day)
+0.00%
52-Week Range
€28.40 - €28.40
All Time High
€43.69
About

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for… Read more